Myriad Launches New GeneSight Psychotropic Patient Collection Kit

Clinicians Seeing Patients Remotely Can Now Offer Home DNA Sample Collection

SALT LAKE CITY, July 01, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home collection kit for the GeneSight Psychotropic test. The kit allows the DNA sample collection typically administered in a clinician’s office to be completed at home. The new direct-to-patient collection kit must still be ordered by a licensed healthcare provider.

“We’ve seen an unprecedented rise in mental health issues including depression and anxiety due to the pandemic. A recent survey from John Hopkins University Bloomberg School of Public Health showing a three-fold increase in the number of adults experiencing psychological distress,” said Mark S. Verratti, president of Myriad Neuroscience and Myriad Autoimmune. “At the same time, more clinicians are practicing telemedicine out of necessity to continue to provide care to their patients. To accommodate this growing need for remote access and innovative solutions, we created this easy-to-use patient collection kit. This process allows clinicians to continue to use the GeneSight test as one tool at their disposal when developing a treatment plan for their patients suffering from depression or anxiety.”

Clinicians who have determined that GeneSight is right for their patient may order the test through the secure, online GeneSight portal and request that the kit be sent directly to the patient. Once the patient receives the kit, they follow a clear process with step-by-step instructions. The kit utilizes a buccal, or cheek swab, the patient can use to collect DNA from the inside of their cheeks. After collecting the sample, the patient puts the swab into a confidential, pre-paid and pre-addressed shipping envelope to return it to the Myriad Neuroscience CLIA and CAP Accredited lab for processing. In approximately two days, the ordering clinician receives the GeneSight report via the secure clinician portal.

To view a sample of the patient home collection kit, click here:

https://www.globenewswire.com/NewsRoom/AttachmentNg/725eca41-afe9-40ab ...

About the GeneSight Psychotropic Test
The GeneSight Psychotropic test is the category-leading pharmacogenomic test for depression medications. The test can help inform doctors about genes that may impact how patients metabolize or respond to certain depression medications. It has been given to more than one million patients by tens of thousands of physicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a doctor as part of a comprehensive medical assessment. Learn more at GeneSight.com.